9th American Society of Gene Therapy annual meeting.
The American Society of Gene Therapy, under the presidency of Mark Kay, held its annual meeting in Baltimore, MD, USA this year. This meeting was well received by academics and industry alike in order to promote research, development and application of gene therapy. Exchange of information, promotion of education and development of clinical translation have been the main aims of this society. On face value, the meeting seems to highlight that gene-based treatment is coming of age. Many drawbacks of gene-based treatments were discussed at this meeting with an intense vigour. Immunology has been the major hurdle in restricting the full realisation of gene therapy in the clinical arena. In summary, the field of gene therapy has progressed from its infancy stage of trying to get it to work, to another stage where attempts are being made to overcome the problems associated with its application, in particular, in relation to human immune responses to the vector and the transgene. This progress should be celebrated and not treated as a failure of this form of therapy, as to make this progress is indeed an achievement for any form of therapy.
Tan
P H
PH
John Radcliffe Hospital, Regional Vascular Unit, Nuffield Department of Surgery, John Radcliffe Hospitals NHS Trust, University of Oxford, Headley Way, Oxford, OX3 9DU, UK. p.tan@imperial.ac.uk
D015316:Genetic Therapy / Q000331:legislation & jurisprudence / Q000379:methods* / Q000639:trends; D005822:Genetic Vectors; D006801:Humans; D007107:Immune System; D007167:Immunotherapy; D019076:Transgenes